Bimekizumab clinical efficacy responses translate into improvements in patient outcomes to Week 48 in patients with moderate to severe hidradenitis suppurativa: Results from BE HEARD I&II

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS^® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.